Summary & Overview
HCPCS Level II J8515: Cabergoline, Oral, 0.25 mg
HCPCS Level II code J8515 designates cabergoline, oral, 0.25 mg—an oral dopamine agonist used in several endocrine and neurology indications. Nationally, accurate coding for oral specialty medications like cabergoline matters for pharmacy reimbursement, claims adjudication, and managing outpatient drug benefit utilization. This code identifies the specific unit strength for billing and recordkeeping when cabergoline is dispensed in outpatient settings.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the clinical and billing context for J8515, typical sites of service where the code is used, and the scope of information available for national benchmarking. The publication also outlines what is and is not available in the input data, noting where payor-specific coverage policies, utilization benchmarks, or diagnosis linkages would normally appear.
This summary provides clinicians, billing staff, and policy analysts with a clear reference to the code’s intent and operational setting. It frames expectations for downstream sections covering modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and payer-specific policy details. Data not available in the input is explicitly marked for transparency.
Billing Code Overview
HCPCS Level II code J8515 represents cabergoline, oral, 0.25 mg. This code is used for billing the oral formulation of cabergoline in 0.25 milligram units.
Service Type: Oral medication administration / outpatient pharmaceutical supply
Typical Site of Service: Outpatient pharmacy or clinic outpatient setting where oral medications are furnished to patients
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old female with hyperprolactinemia secondary to a pituitary microadenoma presents to an endocrinology clinic for initiation of dopamine agonist therapy. The clinician prescribes oral J8515 (cabergoline, oral, 0.25 mg) to be taken twice weekly, with baseline pregnancy testing and monitoring of serum prolactin levels. The clinical workflow includes: initial evaluation and documentation of symptoms (galactorrhea, amenorrhea, infertility), ordering baseline serum prolactin and pregnancy test, counseling on adverse effects (orthostatic hypotension, nausea), providing the prescription for J8515, scheduling a follow-up visit in 4–6 weeks for prolactin level reassessment and dose adjustment, and arranging periodic cardiac valvular assessment if long-term high-dose therapy is anticipated. Pharmacy dispensing and standard medication administration documentation are completed in the outpatient record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; generally not applied when a specific modifier is appropriate |
22 |